Genomic Valley Biote News

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Yogesh Agrawal & Parul Agrawal

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Yogesh Agrawal

Please find enclosed herewith the Un- Audited Standalone financial result for the quarter ended on June 30,2024 .

Genomic Valley Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2024 ,inter alia, to consider and approve Intimation regarding Holding of Board Meeting on 29th July, 2024 to consider Un-Audited Financial Results for the quarter ended June 30, 2024

Please find enclosed

Non applicability of Reg 23(9) is enclosed herewith

Outcome of the Board Meeting is enclosed.

Compliance certificate under Reg 40(10) of LODR Reg

Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018

Issue of Duplicate Share Certificate

Newspaper Publication of Un-Audited Financial Results for the quarter and nine months ended 31.12.2023

Change in Directorate

Results - Financial Results for 31.12.2023

Newspaper Advertisement of Notice of Board Meeting

Closure of Trading Window

Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018

Resignation of Non-Executive Independent Director of the Company

Reconstitution of Committees

Change in Management

Change in Directorate